CD28 is a promising target for treating alopecia areata with belatacept.
March 2026 in “Acta Pharmaceutica Sinica B” Microneedles show promise for improving hair regrowth in alopecia.
February 2026 in “Pharmaceuticals” KRDQN effectively predicts adverse drug reactions with high accuracy and clear explanations.
February 2026 in “Journal of the American Academy of Dermatology” Managing skin diseases during pregnancy and postpartum requires careful consideration of treatment safety and dosing to protect both mother and baby.
January 2026 in “Journal of Radiation Research” 53BP1 focus analysis in hair cells can help estimate radiation doses.
January 2026 in “Health Food & Biotechnology” A hair serum with 3% keratin from chicken feathers made hair smoother, shinier, and more elastic.
January 2026 in “National Journal of Pharmaceutical Sciences” A new method using gas chromatography effectively measures minoxidil in drugs and biological samples.
November 2025 in “Journal of Pharmaceutical Research International” Ustekinumab and vedolizumab can help some ulcerative colitis patients with hair regrowth, but results vary.
October 2025 in “Australasian Journal of Dermatology” Combination therapies may be more effective for treating Folliculitis Decalvans than antibiotics alone.
July 2025 in “Journal of Investigative Dermatology” Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.
June 2025 in “British Journal of Dermatology” Denosumab may cause alopecia areata.
Early genetic testing and new therapies like secukinumab are crucial for managing Netherton syndrome effectively.
January 2025 in “International Journal of Molecular Sciences” Psoriasis involves immune and genetic factors, and understanding these can improve treatments.
Higher pre-pregnancy BMI is linked to more stress in mothers and more behavioral problems in two-year-old children.
January 2025 in “Dermatology Review” Advancements in dermatology are improving diagnosis, treatment options, and patient care.
January 2025 in “Stem Cells International” Epigenetic changes in skin cells contribute to aging, but targeting these changes may offer new antiaging treatments.
December 2024 in “JEADV Clinical Practice” COVID-19 vaccination is generally safe for people with Hidradenitis Suppurativa.
November 2024 in “Revista fisio&terapia.” JAK inhibitors show promise for treating Alopecia Areata, but more research is needed for better, accessible treatments.
October 2024 in “Andrology” Paternal drug exposure can harm fertility, pregnancy outcomes, and offspring health, with specific drugs linked to various reproductive issues.
October 2024 in “Journal of Education Health and Sport” Alopecia areata treatment should be personalized, using topical or systemic therapies based on severity, with promising options like JAK inhibitors needing more research.
October 2024 in “Canadian Journal of Health Technologies” Olumiant should be covered for severe alopecia areata if certain conditions are met.
September 2024 in “Вопросы современной педиатрии” Dupilumab helped an 11-year-old boy regrow hair and reduce skin rashes.
September 2024 in “Journal of the American Academy of Dermatology” Organizations help patients access discounts for expensive dermatology medications.
August 2024 in “Polo del Conocimiento” Scalp psoriasis is treated with topical therapies, phototherapy, and systemic medications.
July 2024 in “Nursing Research” Hair and nail cortisol levels can show long-term stress in young males.
Personalized care and evidence-based treatments are crucial for managing skin and hair conditions.
May 2024 in “Journal of Education, Health and Sport” Current treatments for folliculitis decalvans include antibiotics, isotretinoin, and potential new therapies like botulinum toxin A and PRP.
May 2024 in “Frontiers in Medicine” Targeted immunological therapies offer safer and more effective treatments for skin conditions like eczema and psoriasis.
April 2024 in “Medical & clinical research” More research is needed to find the best long-term treatments for Alopecia Areata.
February 2024 in “Curēus” Secukinumab can cause hair loss, which may improve after stopping the medication.